Can biologic therapies be withdrawn or tapered in psoriatic arthritis?

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Moverley, Anna R ^a   Coates, Laura C ^a   Helliwell, Philip S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Biologic drugs; Disease flare; Psoriatic arthritis; Treatment

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RELAPSE; REMISSION; RISK REDUCTION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885728309     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. GLADMAN DD, ANTONI C, MEASE P, CLEGG DO, NASH P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. II): ii14-ii7.
2. ZACHARIAE H: Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441-7.
3. RITCHLIN CT, KAVANAUGH A, GLADMAN DD et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94
4. KINGSLEY GH, KOWALCZYK A, TAYLOR H et al.: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012; 51: 1368-77.
5. HEIBERG MS, KAUFMANN C, RODEVAND E et al.: The comparative effectiveness of anti- TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007; 66: 1038-42.
6. CANTINI F, NICCOLI L, NANNINI C et al.: Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008; 47: 872-6.
7. ARAUJO E, FINZEL S, SCHREIBER D, KLEYER A, ENGLEBRECHT M, SCHETT G: High incidence of flare after discontinuation of disease modifying anti-rheumatic drugs in patients with psoriatic arthritis. Ann Rheum Dis 2013; 72 (Suppl. 3): 679.
8. WILLIAMS JP, MEYERS JA: Immune-mediated inflammatory disorders (I.M.I.D.s): The economic and clinical costs. Am J Manag Care 2002; 8: S664-S81.
9. HUSCHER D, MERKESDAL S, THIELE K, ZIEDLER H, SCHNEIDER M, ZINK A: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematous in Germany. Ann Rheum Dis 2006; 65: 1175-83.
10. JONSSON B, REHNBERG C, BORGQUIST L, LARSSON S: Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand 1992; 63: 207-12.
11. KVIEN T: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004; 22 (2 Suppl.): 1-12.
12. PUGNER K, SCOTT D, HOLMES J, HIEKE K: The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 129: 305-20.
13. FELDMAN S, FLEISCHER A, REBOUSSIN D, RAPP S, BRADHAM D, CLARK A: The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-9.
14. JONSSON B, KAARELA K, KOBLET G: Economic consequences of the progression of rheumatoid arthritis: a Markov model: Stockholm: Stockholm School of Economics; 1997.
15. KOBELT G, EBERHARDT K, JONSSON L, JONSSON B: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347-56.
16. McINTOSH E: Clinical audit: the cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781-90.
17. KOBELT G, JONSSON L, LINDGREN P, YOUNG A, KE: Modelling the progression of rheumatoid arthritis:a two-country model to estimate costs to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46: 2310-9.
18. MICHAUD K, MESSER J, CHOI H, WOLFE F: Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 2750-62.
19. ARMSTRONG D, McCAUSLAND E, WRIGHT G: The impact of anti- TNF-alpha therapy on the nature of service provision. Rheumatology 2006; 45: 112.
20. OLIVIERI I, SALVARANI C, CAULI A, LUBRANO E, SPADARO A: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 2008; 47: 1664-70.
21. KAVANAUGH A, FRANSEN J: Defining remission in psoriatic arthritis. Clin Exp Rheum 2006; 24 (6 Suppl. 43): S-83.
22. GLADMAN DD, HING EN, SCHENTAG CT, COOK RJ: Remission in psoriatic arthritis. J Rheumatol 2001 May; 28: 1045-8.
23. COATES LC, HELLIWELL PS: Validation of Minimal Disease Activity (MDA) criteria for Psoriatic Arthritis using Interventional Trial Data. Arthritis Care Res (Hoboken) 2010; 62: 965-9.
24. SALEEM B, KEEN H, GOEB V et al.: Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. Ann Rheum Dis 2010; 69: 1636-42.
25. CRAIG JC, WEBSTER AC, LOY C: How long should treatments be continued?. BMJ 2010; 341: c4102.
26. COATES LC, FRANSEN J, HELLIWELL PS: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.